Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
Search for other papers by Shumei Kato in
Current site
Google Scholar
PubMed
Search for other papers by Vivek Subbiah in
Current site
Google Scholar
PubMed
Search for other papers by Razelle Kurzrock in
Current site
Google Scholar
PubMed
Dr. Kato is an Assistant Professor of Medicine at University of California, San Diego. He treats a wide variety of cancers, including gastrointestinal cancer and rare tumors. His research focus is investigating the novel targeted therapy approach as well as understanding the resistant mechanism from targeted agents.
The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.
Dr. Subbiah, a clinical trials investigator, is currently an Assistant Professor in the Department of Investigational Cancer Therapeutics (A Phase 1 Program), Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center. Dr. Subbiah has a unique training background in that he is one of the few physicians in the nation to have training in oncology in both adults and children. He is primarily involved in translational cancer research and the design/conduct of early-phase, biomarker-driven clinical trials, with a special interest in precision oncology and immunoconjugate trials. He is a major advocate for precision oncology and personalized medicine.
Dr. Subbiah receives research funding for clinical trials from Roche/Genentech, Novartis, Bayer, GSK, Nanocarrier, Vegenics, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, and Bluprint Medicines.
Dr. Kurzrock is a Senior Deputy Director, UCSD Moores Cancer Center; Director, Center for Personalized Cancer Therapy and Clinical Trial Office; and Chief, Division of Hematology and Oncology at University of California, San Diego. She developed the largest phase I clinical trials department in the world at The University of Texas MD Anderson Cancer Center before being appointed at University of California, San Diego. At the Center for Personalized Cancer Therapy, she uses advanced molecular technologies to match patients with cancer with genomically targeted therapies and immunotherapy to optimize the chance for response.
She receives consultant fees from X-biotech and from Actuate Therapeutics, as well as research funds from Genentech, Pfizer, Sequenom, Guardant, Foundation Medicine, and Merck Serono, and has an ownership interest in CureMatch Inc.
© 2019-2024 National Comprehensive Cancer Network